Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

AndroGel (Testosterone Topical) Gynecomastia Severity Grading Rubric

By
Published Updated Last reviewed
10 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Gynecomastia, 180 days / generic testosterone gel 1% label: 1% at 50 mg, 0% at 75 mg, 3% at 100 mg [2]
  • Gynecomastia, 3 years / generic testosterone gel 1% label: 2.5% of 162 men [2]
  • Mechanism / Aromatase converts testosterone to estradiol; estrogen stimulates breast tissue and androgen inhibits it [4][5]
  • Classification paper / Simon and colleagues, 1973 [1]
  • Surgical series by grade / Minor complications in 53%, more often with grade II or III [10]
  • Medical options in reviews / Aromatase inhibitors and tamoxifen [3]
  • Surgery / When gynecomastia does not resolve spontaneously or with medical therapy [5]

Is there a rubric for AndroGel gynecomastia?

Grading is clinical. The Simon paper is a 1973 classification and surgical-correction paper, and its title describes classification of gynecomastia in general, not a testosterone-specific grading system [1]. A 1999 surgical series of 100 patients reported results by grade, with minor complications in 53% of patients and significantly more often in grade III or II gynecomastia [10]. The generic testosterone gel 1% label reports how often gynecomastia occurred by dose, not how severe it was [2].

What the testosterone gel label reports

The prescribing information for generic testosterone gel 1% reports gynecomastia in a 180-day Phase 3 trial. The rates were 1% with 50 mg (77 men), 0% with 75 mg (40 men) and 3% with 100 mg (78 men) [2]. Breast pain was reported by 1%, 3% and 1%, respectively [2]. In a 3-year flexible-dose extension study of 162 men, gynecomastia was reported in 2.5% [2]. This is not an AndroGel label, so these are not AndroGel-specific rates.

Why testosterone gel can cause gynecomastia

Aromatase converts androgens to estrogens, and it is expressed in the testes and other male organs [4]. In the breast, estrogens stimulate tissue growth and androgens inhibit it; most gynecomastia comes from deficient androgen action or excessive estrogen action [5]. A careful physical examination usually distinguishes benign gynecomastia from breast cancer [5].

What reviews say about treatment

A 2025 narrative review says gynecomastia related to testosterone replacement is usually managed with aromatase inhibitors and tamoxifen [3]. A 2004 report of two men with testosterone-related gynecomastia described successful treatment with the aromatase inhibitor anastrozole; case reports do not establish a standard dose or a response rate [8].

In one review of records from 68 men with idiopathic gynecomastia, complete resolution occurred in 18 of 23 men (78.2%) treated with tamoxifen 20 mg daily and 8 of 20 (40%) treated with danazol; five men in the tamoxifen group had recurrence [9]. Those men did not have testosterone-induced gynecomastia.

Surgery may be necessary when gynecomastia does not resolve spontaneously or with medical therapy [5]. In the retrospective series of 100 patients, all but two underwent subcutaneous mastectomy, and 86% were satisfied with the result [10]. The series was not specific to testosterone gel.

Frequently asked questions

Is there a grade I to IV rubric for AndroGel gynecomastia?
The cited papers describe general surgical classification, not a testosterone-specific scale: a 1973 paper on classification and surgical correction of gynecomastia [1] and a surgical series that reported results by grade [10]. The generic testosterone gel 1% label reports gynecomastia frequency by dose rather than severity [2].
How common is gynecomastia with testosterone gel?
In a 180-day trial in the generic testosterone gel 1% label, gynecomastia was reported by 1% of men on 50 mg, 0% on 75 mg and 3% on 100 mg [2]. In a 3-year extension, 2.5% of 162 men were reported with gynecomastia [2].
Does a higher testosterone gel dose cause more gynecomastia?
The 180-day trial rates were 1% at 50 mg, 0% at 75 mg and 3% at 100 mg, so the numbers do not show a steady rise with dose [2]. The dose groups were small: 77, 40 and 78 men [2].
Does gynecomastia from testosterone gel go away on its own?
The gynecomastia review notes that some cases resolve spontaneously, using pubertal gynecomastia as the example [5]. It does not describe a resolution rate for testosterone-induced gynecomastia.
What treatments are described for testosterone-related gynecomastia?
A 2025 review says it is usually managed with aromatase inhibitors and tamoxifen [3]. Anastrozole has been reported to treat two cases [8], and surgery may be needed when medical therapy does not resolve the tissue [5].

References

  1. Simon BE, Hoffman S, Kahn S. Classification and surgical correction of gynecomastia. Plast Reconstr Surg. 1973;51(1):48-52. Classification and surgical correction of gynecomastia
  2. U.S. National Library of Medicine, DailyMed. Testosterone gel 1% topical (generic) prescribing information, effective 2025-09-30. Testosterone gel 1% topical prescribing information
  3. Basheer B, Ila V, Barros R, Mesquita F, Lopes LS, Lima VFN, et al. Management of Adverse Effects in Testosterone Replacement Therapy. Int Braz J Urol. 2025;51(3). Management of Adverse Effects in Testosterone Replacement Therapy
  4. Cooke PS, Nanjappa MK, Ko C, Prins GS, Hess RA. Estrogens in Male Physiology. Physiol Rev. 2017;97(3):995-1043. Estrogens in Male Physiology
  5. Narula HS, Carlson HE. Gynaecomastia--pathophysiology, diagnosis and treatment. Nat Rev Endocrinol. 2014;10(11):684-98. Gynaecomastia--pathophysiology, diagnosis and treatment
  6. Testosterone Information | FDA. Testosterone Information | FDA
  7. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. Cardiovascular Safety of Testosterone-Replacement Therapy
  8. Rhoden EL, Morgentaler A. Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. Int J Impot Res. 2004;16(1):95-7. Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole
  9. Ting AC, Chow LW, Leung YF. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg. 2000;66(1):38-40. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia
  10. Colombo-Benkmann M, Buse B, Stern J, Herfarth C. Indications for and results of surgical therapy for male gynecomastia. Am J Surg. 1999;178(1):60-3. Indications for and results of surgical therapy for male gynecomastia
Evidence overview for AndroGel (Testosterone Topical) Gynecomastia Severity Grading Rubric